Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics, Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Korro Bio (KRRO), Ardelyx (ARDX) and Kymera Therapeutics (KYMR). ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KYMR	$107.52	+1.04%	463.57K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KYMR	$107.52	+1.0%	463.57K
3
4
5
6

KYMR

KYMR

Get Kymera Therapeutics, Inc. Data in Excel

Get Kymera Therapeutics, Inc. Data in Excel